Skip to content

Treatment of Myocardial Infarction With Bone Marrow Derived Stem Cells

Treatment of Myocardial Infarction With Autologous Bone Marrow Derived Stem Cells

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00275977
Enrollment
10
Registered
2006-01-12
Start date
2006-02-28
Completion date
2007-03-31
Last updated
2010-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Keywords

Stem cell, autologous bone marrow transplantation, Myocardial infarction

Brief summary

The aim of the study is to investigate whether infusion of autologous bone marrow derived stem cells can improve cardiac function in the aftermath of a myocardial infarction.

Detailed description

Primary coronary intervention within a few hours of a myocardial infarction has greatly reduced mortality as well as the risk of developing chronic heart failure. There are though still a large number of patients that develop symptoms of heart failure in the form of fatigue and breathlessness with physical exertion in spite of medical treatment. With the advance in stem cell technology there is now hope for the possibility of regenerating/repairing dead myocardial tissue, hence improving cardiac function. The current study is a pilot study that is going to precede a later double blinded randomized study. The aim of the study is to evaluate patient safety, optimize procedures, and to be used in power calculation in the design of the following study.

Interventions

PROCEDURECoronary catherization and stem cell infusion

Sponsors

Odense University Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Chestpain * Troponin T, \> 0,1ng/ml * Succesfull revascularization of culprit lesion with PCI. * No more than stenosis of 2 major epicardiel coronary arteries.

Exclusion criteria

* Cardiogenic shock * Known LVEF\<45% * Cardiomyopathy * Atrialfibrillation or fluctuation * Takyarytmia * Infection * Chronic inflammatory disease

Design outcomes

Primary

MeasureTime frame
Safety

Secondary

MeasureTime frame
Change in left ventricular funtion at 4 months followup using contrast enhanced echocardiography

Countries

Denmark

Contacts

Primary ContactMalthe AM Kristiansen, MD
mkristiansen@health.sdu.dk+45 65504081

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026